Destiny Pharma’s novel antibiotic asset clears safety review

11th August 2020 Uncategorised 0

Independent Data Monitoring Committee recommended continuing Phase IIb study

More: Destiny Pharma’s novel antibiotic asset clears safety review
Source: News